ADRBK1 (Ab-86) Antibody

What is ADRBK1/GRK2 and why is it important in research?

ADRBK1/GRK2 is a ubiquitous cytosolic enzyme that specifically phosphorylates activated forms of beta-adrenergic and related G-protein-coupled receptors (GPCRs). It plays a critical role in agonist-specific desensitization observed at high agonist concentrations. The ADRBK1 gene spans approximately 23 kb and contains 21 exons .

Research significance extends to cardiovascular conditions, as heart failure is accompanied by severely impaired beta-adrenergic receptor function. An important mechanism for rapid desensitization of beta-AR function is agonist-stimulated receptor phosphorylation by beta-ARK1 (another name for ADRBK1), which is known to be elevated in failing human heart tissue. Abnormal coupling of beta-adrenergic receptor to G protein is involved in heart failure pathogenesis, making ADRBK1 inhibition a potential novel therapeutic approach .

What forms of ADRBK1/GRK2 antibodies are available for research?

Available ADRBK1/GRK2 antibodies exhibit various characteristics tailored to specific research needs:

Data compiled from multiple sources .

How should I determine the optimal working dilution for an ADRBK1/GRK2 antibody in my experiment?

Determining the optimal working dilution requires systematic titration based on manufacturer recommendations and your specific experimental conditions:

• Begin with the manufacturer's suggested dilution range (e.g., 1:500-1:3000 for WB, 1:50-1:100 for IHC-P)

• Perform a titration experiment using 3-5 dilutions across the recommended range

• Include appropriate positive and negative controls (including a GRK2/3 knockout cell line if available)

• Analyze signal-to-noise ratio and specificity for each dilution

• Select the dilution that provides optimal signal with minimal background

Note that optimal dilutions/concentrations should ultimately be determined by the end user as they depend on sample type, protein expression levels, and detection method . For novel applications not tested by the manufacturer, more extensive optimization may be required.

How can I validate the specificity of an ADRBK1 antibody for western blotting?

Validating antibody specificity for ADRBK1/GRK2 in western blotting requires multiple controls and considerations:

• Positive control: Use tissues/cells known to express high levels of ADRBK1/GRK2

• Negative control: Include GRK2 knockout (ΔGRK2) cells as created through CRISPR/Cas9 technology

• Molecular weight verification: Confirm detection at the expected molecular weight of 79.6 kDa

• Peptide competition: Pre-incubate antibody with immunizing peptide to confirm specific binding

• Cross-reactivity assessment: Test with related proteins (e.g., GRK3/ADRBK2) to ensure specificity

For western blotting protocols with ADRBK1 antibodies, researchers typically use 1:1000 dilution , but this should be optimized for your specific antibody and experimental system.

What are the key considerations for using ADRBK1 antibodies in immunohistochemistry?

When conducting immunohistochemistry (IHC) with ADRBK1/GRK2 antibodies, consider:

• Fixation method: Formalin-fixed paraffin-embedded (FFPE) tissues require antigen retrieval; optimize based on antibody specifications

• Antibody dilution: Typically 1:50-1:100 for IHC-P applications

• Positive control tissues: Include tissues known to express ADRBK1/GRK2

• Blocking: Use appropriate blocking agents to reduce background

• Detection system: Choose appropriate secondary antibody and visualization system

Note that some ADRBK1 antibodies have not been tested in IHC for frozen sections (IHC-F) , so additional validation would be required for this application.

How can I implement ADRBK1 antibodies in ELISA-based quantification methods?

For ELISA-based quantification of ADRBK1/GRK2:

• Sandwich ELISA principle: Commercial kits employ antibodies specific for ADRBK1 pre-coated onto microplates. Standards and samples are added, followed by detection antibody, enzyme conjugate, and substrate

• Sample preparation: Validated for rat serum, plasma, cell culture supernatants, tissue homogenates, and other biological fluids

• Controls: Include standard curves and positive/negative controls

• Cross-reactivity: Consider potential cross-reactivity with other GRK family proteins

• Sensitivity: Evaluate the detection limits of your specific kit/antibody system

For antibody dilution in custom ELISA setups, a dilution of 1:10000 is often recommended for anti-GRK2 antibodies .

How can ADRBK1/GRK2 knockout models be generated and validated using ADRBK1 antibodies?

Creating and validating GRK2 knockout models involves:

• CRISPR/Cas9 gene editing: Target the ADRBK1 locus using appropriate guide RNAs

• Clone isolation: Single clones containing modifications of all alleles should be identified

• Verification methods:

  • Sequencing and indel detection by amplicon analysis

  • Western blotting with validated anti-ADRBK1 antibodies to confirm protein absence

  • Functional assays to verify knockout effects on signaling pathways

Research has successfully created individual and combined GRK2 and GRK3 KO HEK293A cells (ΔGRK2, ΔGRK3, and ΔGRK2/3) using CRISPR/Cas9 technology. Clones were identified with insertions or deletions in the ADRBK1 locus (GRK2) leading to frameshifts as confirmed by sequencing and indel detection .

How can I study the role of ADRBK1/GRK2 in β-arrestin recruitment and receptor internalization?

To investigate GRK2's role in β-arrestin recruitment and receptor internalization:

• Experimental models: Use both pharmacological inhibition (e.g., CMPD101) and genetic approaches (ΔGRK2 and ΔGRK2/3 cells)

• β-arrestin recruitment assays:

  • Energy transfer-based assays (BRET) measuring recruitment of GFP2-β-arrestin2 to receptor-RlucII

  • Enhanced bystander BRET (ebBRET) assay where recruitment of Venus-β-arrestin2 to receptors brings it into proximity with rGFP at the plasma membrane

• Internalization assays: Measure receptor surface expression before and after agonist stimulation

• Antibody application: Use validated ADRBK1 antibodies to confirm knockout or knockdown efficiency

• Kinetic analysis: Examine time-dependent effects (e.g., 6 min vs. 60 min stimulation)

Research has shown that β-arrestin2 recruitment was decreased in ΔGRK2 and ΔGRK2/3 cell lines after stimulation with agonists like DAMGO, fentanyl, and loperamide. The maximum responses in these cells were 51-59% and 38-42%, respectively, of the response in parental cells .

What techniques can be used to investigate ADRBK1/GRK2 interactions with other proteins using ADRBK1 antibodies?

Advanced techniques for studying ADRBK1/GRK2 protein interactions include:

• Co-immunoprecipitation (Co-IP): Use ADRBK1 antibodies to pull down protein complexes

• Proximity ligation assay (PLA): Detect protein-protein interactions in situ

• FRET/BRET: Monitor real-time interactions in live cells

• Mass spectrometry: Identify novel interaction partners after immunoprecipitation

• Yeast two-hybrid screening: Discover potential binding partners

ADRBK1/GRK2 has multiple known interaction partners including:

Table compiled from published research .

What are common causes of false positives or background when using ADRBK1 antibodies, and how can these be minimized?

Common causes of false positives or high background when using ADRBK1 antibodies include:

• Antibody concentration: Too high concentration increases non-specific binding

  • Solution: Optimize antibody dilution through careful titration (e.g., test range from 1:500-1:3000 for WB)

• Insufficient blocking: Inadequate blocking allows non-specific binding

  • Solution: Use appropriate blocking agents (e.g., 5% BSA or non-fat milk) and optimize blocking time

• Cross-reactivity: Antibody binding to related proteins

  • Solution: Select antibodies with validated specificity; some ADRBK1 antibodies are predicted to react with Mouse, Rat, and Cow GRK2

• Sample quality: Degraded proteins or contaminated samples

  • Solution: Ensure proper sample preparation and storage; add protease inhibitors

• Detection system sensitivity: Overly sensitive detection systems amplify background

  • Solution: Adjust exposure times and detection reagent concentrations

For protocol optimization, always include appropriate negative controls, particularly GRK2 knockout cells if available .

How should ADRBK1 antibodies be stored and handled to maintain optimal activity?

Optimal storage and handling conditions for ADRBK1 antibodies:

• Storage temperature: Aliquot and store at -20°C to avoid repeated freeze/thaw cycles

• Buffer conditions: Typically stored in PBS with 0.09% sodium azide or PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 0.02% sodium azide and 50% glycerol

• Aliquoting: Divide into small aliquots upon receipt to avoid repeated freeze/thaw cycles

• Working solution preparation: Dilute only the amount needed for experiments

• Shipping conditions: Typically shipped on ice packs; verify integrity upon arrival

• Expiration: Check manufacturer's recommendations for shelf life

Improper storage can lead to antibody degradation, aggregation, or loss of specificity, resulting in decreased performance in applications.

How can I validate that my ADRBK1 antibody is detecting phosphorylation-specific states of the target?

To validate phosphorylation-specific detection:

• Phosphatase treatment: Treat half of your sample with lambda phosphatase and compare antibody reactivity

• Phosphomimetic mutants: Test antibody against phosphomimetic (S/T to D/E) and phospho-dead (S/T to A) mutants

• Stimulation experiments: Compare antibody reactivity in basal vs. stimulated conditions known to increase ADRBK1 phosphorylation

• Phosphorylation-specific controls: Use recombinant proteins with verified phosphorylation states

• Mass spectrometry validation: Confirm phosphorylation states at specific residues in immunoprecipitated samples

For studying GRK2's role in receptor phosphorylation, consider that GRK2 itself can be phosphorylated by other kinases (e.g., EGFR), which activates its catalytic function and enhances its ability to phosphorylate receptors like opioid DOR and dopamine D3R .

How can ADRBK1 antibodies be used to investigate the role of GRK2 in receptor desensitization mechanisms?

To investigate GRK2's role in receptor desensitization:

• Comparative analysis: Use ΔGRK2 cells alongside pharmacological inhibitors (e.g., CMPD101) to distinguish GRK2-specific effects

• Time-course experiments: Monitor receptor phosphorylation, β-arrestin recruitment, and internalization over time

• Receptor mutants: Study phosphorylation-deficient receptor mutants to identify GRK2-specific sites

• Antibody applications:

  • Western blotting with phospho-specific antibodies to monitor receptor phosphorylation

  • Immunoprecipitation of GRK2 complexes to identify interacting proteins

  • Immunofluorescence to track subcellular localization during signaling

Research has shown that GRK2/3 inhibitor CMPD101 decreases μ-opioid receptor internalization and β-arrestin2 recruitment with IC₅₀ values of 1.8 μM and 0.95 μM, respectively. At concentrations ≤10 μM, CMPD101 specifically inhibits GRK2/3 with effects comparable to ΔGRK2/3 cell lines .

What are emerging approaches to study ADRBK1/GRK2 in disease models and potential therapeutic applications?

Emerging approaches for studying ADRBK1/GRK2 in disease contexts include:

• Conditional tissue-specific knockout models: Isolate GRK2 function in specific tissues

• Patient-derived cells: Examine GRK2 expression/function in disease-relevant primary cells

• Phosphoproteomics: Identify GRK2 substrates on a global scale

• Small molecule inhibitors: Test GRK2-specific inhibitors as potential therapeutics

• Gene therapy approaches: Target GRK2 expression in disease models

Heart failure represents a key disease model for GRK2 research, as it is characterized by severely impaired beta-adrenergic receptor function. GRK2 (beta-ARK1) is elevated in failing human heart tissue, and abnormal coupling of beta-adrenergic receptors to G proteins contributes to heart failure pathogenesis. Inhibition of ADRBK1 has been proposed as a novel therapeutic approach for heart failure .

How can multiplexed imaging approaches be implemented with ADRBK1 antibodies to study spatial regulation of GPCR signaling?

Advanced multiplexed imaging with ADRBK1 antibodies:

• Multi-color immunofluorescence: Combine ADRBK1 antibodies with antibodies against receptors, arrestins, and signaling molecules

• Live-cell imaging: Use fluorescently tagged proteins alongside immunolabeling of fixed timepoints

• Super-resolution microscopy: Implement STORM, PALM, or SIM for nanoscale resolution of signaling complexes

• Expansion microscopy: Physically expand samples to enhance resolution of conventional microscopes

• Protocol optimization for multiplexing:

  • Careful selection of antibodies from different host species

  • Sequential labeling approaches to avoid cross-reactivity

  • Use of appropriate controls for each antibody

For immunofluorescence protocols, researchers typically fix cells with 4% paraformaldehyde, permeabilize with 0.1% Triton X-100, block with 1% BSA in PBS, and incubate with primary antibodies overnight at 4°C. After washing, cells are incubated with secondary antibodies (e.g., AlexaFluor 488 Goat anti-Rabbit IgG) for 2 hours at room temperature under dim light, with nuclei counterstained using H33342 .